α-Galactosylceramide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

α-半乳糖神经酰胺是一种合成糖脂，具有抗肿瘤和免疫刺激作用，是一种非常有效的 NKT 细胞激动剂，可有效结合 CD1d。 α-半乳糖神经酰胺和CD1d的复合物可以与NKT细胞的T细胞抗原受体结合。

α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.(In Vitro):Stimulation of activated Vα24+ NKT cell cultures with α-Galactosylceramide-pulsed monocyte-derived dendritic cells (Mo-DC) has antiproliferative activity against melanoma cells. Antiproliferative effects of Vα24+ NKT cells stimulated by α-Galactosylceramide-pulsed Mo-DCs via soluble mediators have antitumor activity against human melanoma. This effect is mainly due to the release of IFN-γ and, to a lesser extent, IL-12. Other cytokines, including IL-4 and IL-10, are released, but these cytokines have less antiproliferative effects .(In Vivo):α-Galactosylceramide treatment prevents spontaneous, oncogenic, or oncogene-induced primary tumor formation in mice. Consistent with a major role of IFN-γ in NKT cell-mediated tumor responses, the C-glycoside analog of α-Galactosylceramide, which preferentially stimulates IFN-γ production, was even more effective than α-galactose in preventing B16 melanoma metastasis. Ceramides are more effective . α-Galactosylceramide showed potent antitumor activity and stimulated lymphocyte proliferation (LP) in mouse allogeneic mixed lymphocyte reaction (MLR) .

Culture supernatants of activated Vα24+NKT-cell cultures stimulated with α-Galactosylceramide pulsed monocyte-derived dendritic cells (Mo-DCs) exhibits antiproliferative activities against melanoma cells. This effect is predominantly due to release of IFN-γ, and to a lesser extent IL-12. Other cytokines, including IL-4 and IL-10, are released but these cytokines have less antiproliferative effects. Vα24+NKT-cells stimulated by α-Galactosylceramide-pulsed Mo-DCs have anti-tumour activities against human melanoma through antiproliferative effects exerted by soluble mediators.

α-Galactosylceramide treatment can protect against spontaneous, carcinogen-, or oncogene-induced primary tumor formation in mice. Consistent with a prime role for IFN-γ in NKT cell-mediated tumor responses, a C-glycoside analog of α-Galactosylceramide that preferentially stimulated IFN-γ production is even more effective than α-Galactosylceramide at preventing metastases of the B16 melanoma.Since α-Galactosylceramide shows a potent antitumor activity and stimulates the lymphocyte proliferation (LP) on allogeneic mixed lymphocyte reaction (MLR) in the mouse, α-Galactosylceramide is considered to be a nonspecific immunostimulating agent which is a biological response modifier.

α-GalCer | KRN7000

Others

Other Targets

GPR119

——

——

158021-47-7

858.34

C50H99NO9

>98% (HPLC)

In Vitro:?DMSO : 0.5 mg/mL (0.58 mM)

CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC

——

(-20℃)

With Ice Pack

≥ 2 years